pmid,doi,title,journal,year,abstract_length,methods_length,intro_length,existing_tool_count,novel_tool_count,total_tool_count,existing_tools,novel_tools,tool_metadata,tool_sources,is_gff
10339466,,Myeloid malignancies induced by alkylating agents in Nf1 mice.,Blood,1999,1152,0,0,1,3,4,"{""cell_lines"": {""NF1"": ""1a8a362e-e3be-4bc3-be7e-d0a0865b9c31""}, ""antibodies"": {}, ""animal_models"": {}, ""genetic_reagents"": {}, ""computational_tools"": {}, ""advanced_cellular_models"": {}, ""patient_derived_models"": {}, ""clinical_assessment_tools"": {}}","{""cell_lines"": [], ""antibodies"": [], ""animal_models"": [""heterozygous Nf1"", ""Nf1 knockout"", ""heterozygous Nf1 knockout""], ""genetic_reagents"": [], ""computational_tools"": [], ""advanced_cellular_models"": [], ""patient_derived_models"": [], ""clinical_assessment_tools"": []}","{""cell_lines:NF1"": {""context"": ""c syndrome (t-AML and MDS) are severe late complications of treatment with genotoxic chemotherapeutic agents. Children with neurofibromatosis type 1 (NF1) are predisposed to malignant myeloid disorders that are associated with inactivation of the NF1 tumor suppressor gene in the leukemic clone. Recent "", ""confidence"": 0.7999999999999999, ""is_development"": false, ""is_generic"": false, ""is_established"": false, ""section"": ""abstract""}, ""animal_models:heterozygous Nf1"": {""context"": ""sk of t-AML after treatment with alkyating agents. To test this hypothesis, we administered cyclophosphamide or etoposide to cohorts of wild-type and heterozygous Nf1 knockout mice. Cyclophosphamide exposure cooperated strongly with heterozygous inactivation of Nf1 in myeloid leukemogenesis, while etoposide did not"", ""confidence"": 0.7999999999999999, ""is_development"": false, ""is_generic"": false, ""is_established"": false, ""section"": ""abstract""}, ""animal_models:Nf1 knockout"": {""context"": ""fter treatment with alkyating agents. To test this hypothesis, we administered cyclophosphamide or etoposide to cohorts of wild-type and heterozygous Nf1 knockout mice. Cyclophosphamide exposure cooperated strongly with heterozygous inactivation of Nf1 in myeloid leukemogenesis, while etoposide did not. Somatic"", ""confidence"": 0.7999999999999999, ""is_development"": false, ""is_generic"": false, ""is_established"": false, ""section"": ""abstract""}, ""animal_models:heterozygous Nf1 knockout"": {""context"": ""sk of t-AML after treatment with alkyating agents. To test this hypothesis, we administered cyclophosphamide or etoposide to cohorts of wild-type and heterozygous Nf1 knockout mice. Cyclophosphamide exposure cooperated strongly with heterozygous inactivation of Nf1 in myeloid leukemogenesis, while etoposide did not. Somatic"", ""confidence"": 0.7999999999999999, ""is_development"": false, ""is_generic"": false, ""is_established"": false, ""section"": ""abstract""}}","{""cell_lines:NF1"": [""abstract""], ""animal_models:heterozygous Nf1"": [""abstract""], ""animal_models:Nf1 knockout"": [""abstract""], ""animal_models:heterozygous Nf1 knockout"": [""abstract""]}",False
